KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. PMID 38315832 · Blood Adv · 2024-Jun-11 The report is a subgroup analysis of subsequent treatments after second-line therapy in a randomized trial, not the primary analysis of the trial's main comparison. Furthermore, the trial phase (Phase III/IIIb or II/III) is not explicitly established in the provided metadata, which is a required criterion. Therefore, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study. PMID 38723227 · J Clin Oncol · 2024-Jun-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. PMID 38513188 · J Clin Oncol · 2024-Jun-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials. PMID 38851227 · BMJ Open · 2024-Jun-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells. PMID 38849344 · Blood Cancer J · 2024-Jun-07 The study is a pre-specified or post-hoc biomarker analysis from a randomized trial, not the primary or definitive report of the trial's overall results. The trial phase is not established in the metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia. PMID 38452207 · Blood · 2024-Jun-06 The study meets most criteria (oncology, human, randomized, drug intervention, original result, time-to-event endpoint) but fails to explicitly establish the required phase (III/IIIb or II/III) from the provided metadata. Therefore, it is not eligible for inclusion in this specific oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Physical rehabilitation program for cardiorespiratory health and quality of life among breast cancer survivors in UAE: protocol for a randomized control trial. PMID 38835046 · Trials · 2024-Jun-04 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. PMID 38552171 · Cancer Immunol Res · 2024-Jun-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Remote Monitoring App for Endocrine Therapy Adherence Among Patients With Early-Stage Breast Cancer: A Randomized Clinical Trial. PMID 38935379 · JAMA Netw Open · 2024-Jun-03 While the study is a randomized, oncology, human trial with a drug intervention (endocrine therapy), it lacks the required primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The primary outcome is 1-year adherence rate, which is a proportion, not a time-to-event measure. No Kaplan-Meier or HR data are mentioned. Therefore, it does not meet the eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Vegetable Gardening and Health Outcomes in Older Cancer Survivors: A Randomized Clinical Trial. PMID 38900426 · JAMA Netw Open · 2024-Jun-03 The trial is a randomized clinical trial in older cancer survivors, but it evaluates a vegetable gardening intervention (non-drug) for functional/dietary outcomes, not a cancer treatment. It does not involve a Phase III/IIIb or Phase II/III drug trial, nor does it have a time-to-event efficacy endpoint like OS/PFS. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Stereotactic Body Radiotherapy and Liver Transplant for Liver Cancer: A Nonrandomized Controlled Trial. PMID 38857045 · JAMA Netw Open · 2024-Jun-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Supporting ColoREctal Equitable Navigation (SCREEN): a protocol for a stepped-wedge cluster randomized trial for patient navigation in primary care. PMID 38831365 · Implement Sci Commun · 2024-Jun-03 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A randomized control trial to compare mortality in recipients of leucoreduced and non-leucoreduced whole blood transfusion in patients with cancer in Uganda. PMID 38831291 · BMC Cancer · 2024-Jun-03 The record is a human oncology RCT with a time-to-event endpoint and is an original result, but it is excluded because the intervention is a blood product (non-drug) and the trial phase is not definitively established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review. PMID 38829615 · JAMA Netw Open · 2024-Jun-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Two by Two Factorial Design using Metformin and Curcumin for Second Primary Head and Neck Cancer Prevention Trial. PMID 38918654 · Asian Pac J Cancer Prev · 2024-Jun-01 The record is a clinical trial protocol for a Phase IIB/III randomized trial with drug intervention. While it meets oncology, human, randomized, phase, and drug criteria, it is a protocol without results and the primary endpoint is the incidence of second primary tumors, not a time-to-event endpoint like OS, PFS, DFS, etc. Therefore, it is excluded.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Rebamipide gargle and benzydamine gargle in prevention and management of chemo-radiotherapy and radiotherapy-induced oral mucositis in head and neck cancer patients (randomized clinical trial). PMID 38824583 · BMC Oral Health · 2024-Jun-01 The study is a Phase III randomized trial with a drug intervention, but its primary and key secondary endpoints (incidence, onset, duration of oral mucositis) are not time-to-event efficacy endpoints (e.g., OS, PFS).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. PMID 38763154 · Lancet · 2024-Jun-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. PMID 38763153 · Lancet · 2024-Jun-01 The record describes a randomized trial with a drug intervention (androgen deprivation therapy) and a primary time-to-event efficacy endpoint (metastasis-free survival) in prostate cancer, a human malignant neoplasm. It reports original results with hazard ratio and survival percentages. However, the explicit trial phase (e.g., Phase III) is not provided in the title, abstract, or publication metadata. Without confirmation of Phase III/IIIb or Phase II/III status, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
RENAL PROTECTIVE EFFECT AND CLINICAL ANALYSIS OF VITAMIN B 6 IN PATIENTS WITH SEPSIS. PMID 38691102 · Shock · 2024-Jun-01 This is a randomized controlled trial of vitamin B6 in sepsis patients, which is non-oncology. It lacks a primary time-to-event efficacy endpoint, focusing instead on inflammatory, oxidative stress, and renal function biomarkers, ICU stay, and costs.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer-Long-Term Results of a Randomized Clinical Trial. PMID 38662354 · JAMA Oncol · 2024-Jun-01 The record describes a randomized, drug-containing oncology trial with long-term results, which inherently implies a time-to-event primary endpoint. All required criteria are established.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 1 Panel · risk visible
Transoral Robotic Surgery and Radiation Volume Deintensification in Unknown Primary Squamous Cell Carcinoma of the Neck: The Phase 2 FIND Nonrandomized Controlled Trial. PMID 38602692 · JAMA Otolaryngol Head Neck Surg · 2024-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial. PMID 38573643 · JAMA Oncol · 2024-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Morbidity After Mechanical Bowel Preparation and Oral Antibiotics Prior to Rectal Resection: The MOBILE2 Randomized Clinical Trial. PMID 38506889 · JAMA Surg · 2024-Jun-01 Study is an oncology-related randomized trial but lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The intervention is bowel preparation (mechanical and oral antibiotics) for surgical complication reduction, not a drug-containing cancer therapy. The primary endpoint is the Comprehensive Complication Index (morbidity), not a Kaplan-Meier or time-to-event efficacy outcome.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405. PMID 38457761 · J Clin Oncol · 2024-Jun-01 While the record references a Phase III randomized trial with drug intervention and time-to-event endpoints, the abstract and metadata explicitly describe a secondary biomarker/prognostic and predictive analysis (HER2 expression) from the primary trial, not the original primary result report. Therefore, it does not meet the criterion of being an original formal-result report of the primary trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease. PMID 38445644 · Am J Gastroenterol · 2024-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Prognostic evaluation of the Ki-67 labeling system in histological grading of non-small round cell sarcoma: a supplementary analysis of a randomized controlled trial, JCOG1306. PMID 38391203 · Jpn J Clin Oncol · 2024-Jun-01 The record is a supplementary prognostic analysis of a randomized trial, not the original primary result report of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention and primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia. PMID 38385304 · Haematologica · 2024-Jun-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H L B
旧查询独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Refractory and Recurrent Idiopathic Granulomatous Mastitis Treatment: Adaptive, Randomized Clinical Trial. PMID 38372343 · J Am Coll Surg · 2024-Jun-01 The study is a randomized trial evaluating treatments for idiopathic granulomatous mastitis, which is an inflammatory/autoimmune breast condition, not a human malignant neoplasm (cancer). It therefore fails the primary oncology criterion. Furthermore, while randomized and with drug intervention, it lacks a definitive Phase III designation and does not report a time-to-event efficacy endpoint like OS, PFS, or similar; its outcomes are response rates.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer. PMID 38288862 · Cancer · 2024-Jun-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study. PMID 38240789 · Anticancer Drugs · 2024-Jun-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of short-course radiotherapy versus total neoadjuvant therapy in older rectal cancer patients: a randomised pragmatic trial (SHAPERS). PMID 41648032 · ESMO Gastrointest Oncol · 2024-Jun The record is a protocol for a randomized trial with drug interventions and time-to-event endpoints, but it lacks any actual efficacy or safety results (primary data). It is not an original formal-result report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessing the OPRA Trial for surgical oncologists: Safety and feasibility of a total neoadjuvant therapy approach in patients with rectal cancer. PMID 41306768 · Surg Oncol Insight · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A novel application of XPO1 inhibition for the treatment of myelofibrosis. PMID 40454401 · Blood Neoplasia · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial. PMID 39282588 · J Natl Cancer Cent · 2024-Jun The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title/abstract). While it is a randomized, controlled, definitive trial in oncology with a time-to-event endpoint and a drug intervention, the eligibility criterion requiring explicit confirmation of Phase III/IIIb or Phase II/III cannot be met from the given information.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Spending Analysis of Machine Learning-Based Communication Nudges in Oncology. PMID 39036423 · NEJM AI · 2024-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Checkpoint inhibition for early-stage hormone receptor-positive breast cancer. PMID 38913933 · Expert Opin Biol Ther · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Randomized Placebo-Controlled Trial of Topical Capsaicin for Delayed Chemotherapy-Induced Nausea and Vomiting. PMID 38905580 · JCO Glob Oncol · 2024-Jun The study is a randomized, placebo-controlled trial in an oncology supportive care context (CINV) with a drug intervention, but it does not measure a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, TTP, or use Kaplan-Meier/HR analysis for a survival outcome. The primary endpoints are incidence and frequency of nausea/vomiting, not time-to-event outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nutritional impairment, psychological health and quality of life among older adults with advanced cancer: A secondary analysis of a randomized clinical trial. PMID 38898664 · Cancer Med · 2024-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease. PMID 38896547 · Expert Opin Pharmacother · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Anesthesiological and surgical perspectives on using 8 mmHg versus 12 mmHg pneumoperitoneum pressures during robotic radical prostatectomy: Results of a prospective randomized study. PMID 38863292 · Ulus Travma Acil Cerrahi Derg · 2024-Jun 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. PMID 38844309 · Ann Oncol · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A randomised phase II study of extended pleurectomy/decortication preceded or followed by chemotherapy in patients with early-stage pleural mesothelioma: EORTC 1205. PMID 38843916 · Eur Respir J · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparison of SOX and CAPOX in patients with advanced gastric cancer after laparoscopic D2 gastrectomy: A randomized controlled trial. PMID 38826114 · Cancer Med · 2024-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Evaluating the safety and efficacy of a novel polysaccharide hemostatic system during surgery: A multicenter multispecialty prospective randomized controlled trial. PMID 38800121 · Surg Open Sci · 2024-Jun The record describes a randomized, prospective, multicenter trial with an overall survival endpoint in a subgroup of oncology patients. However, the intervention is a polysaccharide hemostatic agent, which is classified as a medical device/hemostatic, not a therapeutic drug as required by the cohort criteria. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. Therefore, it does not meet all eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SafeHeal Colovac Colorectal Anastomosis Protection Device evaluation (SAFE-2) pivotal study: an international randomized controlled study to evaluate the safety and effectiveness of the Colovac Colorectal Anastomosis Protection Device. PMID 38750621 · Colorectal Dis · 2024-Jun 干预为非药物单独策略,未满足药物干预要求。
H L B
旧查询独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. PMID 38740030 · Lancet Oncol · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Carbon ion radiotherapy of hepatocellular carcinoma provides excellent local control: The prospective phase I PROMETHEUS trial. PMID 38737600 · JHEP Rep · 2024-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. PMID 38734019 · Lancet Rheumatol · 2024-Jun This is a randomized, controlled, Phase 3 trial of COVID-19 vaccines in immunocompromised patients (including some with lymphoid malignancies), with immunogenicity (antibody and T-cell response) as the primary endpoint. It is not an oncology-focused trial evaluating a drug intervention for a malignant neoplasm with a time-to-event efficacy endpoint (e.g., OS, PFS). The primary outcome is immunological response, not survival or progression.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and feasibility of chemotherapy followed by liver transplantation for patients with definitely unresectable colorectal liver metastases: insights from the TransMet randomised clinical trial. PMID 38721015 · EClinicalMedicine · 2024-Jun The record describes a randomized trial in human oncology (colorectal liver metastases) with a drug intervention (chemotherapy). However, it does not explicitly establish Phase III or Phase II/III status, and the reported outcomes are feasibility and safety, not a primary or key secondary time-to-event efficacy endpoint. Therefore, it does not meet all eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effects of repetitive transcranial magnetic stimulation on fear of cancer recurrence and its underlying neuromechanism. PMID 38720913 · Contemp Clin Trials Commun · 2024-Jun The record is a protocol for a randomized trial investigating a non-drug intervention (rTMS) for a psychological outcome (fear of cancer recurrence) in breast cancer patients. It lacks results, is not a drug intervention, has no time-to-event endpoint, and does not represent a definitive phase III randomized trial with a drug-containing intervention and a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -